ArticleJAMA network open2026
Racial and Ethnic Disparities in Persistent Chemotherapy-Induced Alopecia Among Women With Breast Cancer.
Article in JAMA network open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
Importance: Persistent chemotherapy-induced alopecia (PCIA) is a distressing adverse effect that can have lasting psychosocial consequences. However, racial and ethnic differences in PCIA incidence and associated distress remain unclear, owing to limited multiracial and multiethnic data. Objective: To evaluate racial and ethnic disparities in the incidence of PCIA and alopecia-related psychological distress among women with breast cancer from baseline to 12 months after completion of chemotherapy. Design, Setting, and Participants: This prospective cohort study was conducted at 2 tertiary cancer centers in the US (August 19, 2015, to December 31, 2021) and South Korea (December 20, 2018, to April 27, 2022). Women (aged ≥18 years) with stage I to III breast cancer who received chemotherapy were included. Data analysis was conducted from June 30 to July 15, 2025. Exposures: Standardized trichoscopic assessments were performed and validated distress questionnaires were administered at baseline and 12 months after treatment. Main Outcomes and Measures: The primary outcome was PCIA incidence, which was defined as hair thickness or density at 12 months after completion of chemotherapy that fell more than 2 SDs below the level measured before chemotherapy. Secondary outcomes included changes in hair density, hair shaft thickness, and alopecia-related distress, measured using the Chemotherapy-Induced Alopecia Distress Scale (CADS). Results: The 304 women (mean [SD] age, 50.3 [10.6] years) in this study were Asian (n = 159 [52.3%]), Black (n = 20 [6.6%]), Hispanic or Latino (n = 17 [5.6%]), or White (n = 108 [35.5%]). At baseline, Asian women had the thickest hair shafts (mean [SD], 83.2 [13.4] µm) but the lowest follicular density (mean [SD], 136.2 [27.6] hairs/34.34 mm2 at ×50 magnification; P < .001). At 12 months, PCIA incidence was highest in Asian women (59 [42.1%]), followed by White (24 [22.2%]), Black (2 [10.0%]), and Hispanic or Latino (1 [5.1%]) women (P = .001). Asian women also had the greatest increase in CADS scores compared with White women, particularly in the emotional (adjusted mean difference, 1.88 [95% CI, 0.92-2.95]) and activity-related (1.55 [95% CI, 0.58-2.52]) domains. Conclusions and Relevance: In this prospective multinational cohort study, significant racial and ethnic disparities were observed in the incidence and psychological effects of PCIA. Asian women experienced the greatest burden. These findings underscore the need for personalized counseling, culturally sensitive psychosocial support, and consideration of pharmacogenetic risks in managing chemotherapy-related alopecia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.